# US 2021/0330690 A1 · Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330690 A1
- Document ID: US20210330690A1
- Status: Published application
- Kind: A1
- Application number: 17/236,393
- Filed: 2021-04-21
- Published: 2021-10-28
- Earliest claimed: 2020-04-22
- Assignees: Hua Medicine (Shanghai) Ltd.
- Applicants: HUA Medicine (Shanghai) Ltd.
- Inventors: Li Chen; Shuang Ren; Jiayi Zhang
- Web page: https://patentgrep.com/patent/US20210330690A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator and a sodium-glucose cotransporter-2 inhibitor.

## Claims

### Claim 1

A method of treating an untreated or treatment-resistant diabetes, comprising administering to a subject in need thereof a therapeutically effective amount of a glucokinase activator and a therapeutically effective amount of a sodium-glucose cotransporter-2 inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the glucokinase activator is (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-methylpentanamide, or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the glucokinase activator is (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-methylpentanamide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the glucokinase activator is ranging from about 0.1 to about 50 mg/kg per day.

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the glucokinase activator is ranging from about 5 to about 1,000 mg per day.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the glucokinase activator is about 150 mg per day.

### Claim 7 (depends on 1)

The method of claim 1, wherein the glucokinase activator is administered orally.

### Claim 8 (depends on 1)

The method of claim 1, wherein the glucokinase activator is administered orally as a tablet.

### Claim 9 (depends on 1)

The method of claim 1, wherein the glucokinase activator is administered twice a day.

### Claim 10 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, phlorizin, remogliflozin, serglifozin, sotagliflozin, or tofogliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, or tofogliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is empagliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is empagliflozin.

### Claim 15 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the sodium-glucose cotransporter-2 inhibitor is ranging from about 1 to about 1,000 mg per day.

### Claim 16 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the sodium-glucose cotransporter-2 inhibitor is ranging from about 5 to about 50 mg per day.

### Claim 17 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the sodium-glucose cotransporter-2 inhibitor is about 25 mg per day.

### Claim 18 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is administered orally.

### Claim 19 (depends on 1)

The method of claim 1, wherein the sodium-glucose cotransporter-2 inhibitor is administered once a day.

### Claim 20 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is a treatment-resistant type-2 diabetes.

### Claim 21 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is a diabetes with persistent hyperglycemia.

### Claim 22 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is a diabetes with persistent hyperglycemia despite pharmacological treatment with at least three oral glucose-lowering medications.

### Claim 23 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is a diabetes with persistent poorly-controlled diabetes despite standard care with three oral glucose-lowering medications.

### Claim 24 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is a diabetes with a glycated hemoglobin level (HbA1c) of no less than about 7%.

### Claim 25 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 64 mmol/mol.

### Claim 26 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is resistant to metformin, a meglitinide, a dipeptidyl peptidase 4 (DPP-4) inhibitor, an SGLT2 inhibitor, an insulin, a sulfonylurea, a thiazolidinedione, a glucagon-like peptide-1 (GLP-1) agonist, or a combination thereof.

### Claim 27 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is resistant to metformin, a DPP-4 inhibitor, an SGLT2 inhibitor, or a combination thereof.

### Claim 28 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is resistant to metformin.

### Claim 29 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is resistant to a DPP-4 inhibitor.

### Claim 30 (depends on 1)

The method of claim 1, wherein the treatment-resistant diabetes is resistant to an SGLT2 inhibitor.

### Claim 31 (depends on 1)

The method of claim 1, wherein the subject is a human.
